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A B S T R A C T
Objectives: The CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to
be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the
CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting.
Methods and materials: An EORTC Group online survey of LS-SCLC practice was distributed to the EORTC LCG
and to members of several European thoracic oncology societies between April and December 2018.
Results: 198 responses were analysed. The majority of respondents (88%, n= 174) were aware of the CONVERT
trial. Radiation oncologists comprised 56% of all respondents. Once-daily (OD) radiotherapy is still the most
commonly used regimen, however the use of concurrent BD radiotherapy increased after the publication of
CONVERT (n= 59/186, 32% prior to and n=78/187, 42% after the publication, p= 0.053). The main reasons
for not implementing BD after the CONVERT publication were logistical issues (n= 88, 44%), inconvenience for
patients (n=56, 28%), and the absence of a statistical survival difference between the two arms in CONVERT
(n=38, 19%). Brain MRI was used by 28% during staging but more than half (60%) of the respondents did not
routinely image the brain during follow-up. The main research questions of interest in LS-SCLC were 1) in-
tegrating novel targeted therapies-immunotherapies (n= 160, 81%), 2) PCI (+/- hippocampal sparing) vs. MRI
surveillance (n= 140, 71%) and, 3) biomarker driven trials (n=92, 46%).
Conclusion: Once daily radiotherapy (60–66 Gy in 30–33 fractions) remains the most prescribed radiotherapy
fractionation, despite the findings suggested by the CONVERT trial.
1. Introduction
Concurrent thoracic chemoradiotherapy (CTRT) is the re-
commended treatment for limited-stage (LS) small-cell lung cancer
(SCLC) patients [1–3]. Hyperfractionated radiotherapy combined with
chemotherapy yields better overall survival (OS) compared with stan-
dard radiotherapy [4]. However, hyperfractionated radiotherapy
schedules have not been widely adopted in routine practice due to
limitations in the design of previous studies [4,5], logistical issues and
an increase in acute toxicity [6,7]. The CONVERT trial is a multi-centre
phase III trial (NCT00433563) that randomly assigned LS-SCLC pa-
tients, with Eastern Cooperative Oncology Group performance score
0–2, to receive either twice-daily (BD; 45 Gy in 30 fractions) or once-
daily (OD; 66 Gy in 33 fractions) radiotherapy starting with the second
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cycle of chemotherapy [8]. Prophylactic cranial irradiation (PCI) was
given if indicated. Survival outcomes did not differ between BD and OD
CTRT (median OS 30 vs. 25 months, respectively), and was higher than
anticipated in both arms. Furthermore, toxicity was similar and lower
than expected with both regimens. As the trial was designed to show
the superiority of OD radiotherapy and was not powered to show
equivalence, BD radiotherapy should continue to be considered the
standard of care in this setting. However, the impact of the CONVERT
trial on daily clinical practice is unclear. Our aim was to assess this
impact and also to identify relevant research questions for future trials
in this setting. Therefore, we conducted a European survey to evaluate
current daily practice in good performance status LS-SCLC patients
suitable for CTRT.
2. Material/methods
A European Organisation for Research and Treatment of Cancer
(EORTC) Lung Cancer Group (LCG) online (Google® form) survey of LS-
SCLC practice was distributed between April and December 2018 to the
EORTC LCG and to members of several European thoracic oncology
societies. The survey was anonymous and strictly confidential. The
questionnaire was divided into five sections: physician’s demographic
data, thoracic CTRT, PCI, diagnostic and follow-up investigations and
future research questions. The survey consisted of 27 questions (5 with
“tick box” response options), and was designed to be completed in
approximately 10min. The survey was reviewed by all EORTC LCG
board members (N=12). A copy of the full survey is available in the
Supporting Information.
The Fisher exact test was used for dichotomous variables compar-
ison. A two-sided P-value<0.05 was considered significant.
3. Results
198 responses were analysed: 111 respondents were radiation on-
cologists (56%), 59 were medical oncologists (30%), and 28 were
pulmonologists (14%). Overall, 84% of respondents had>5 years’
experience of treating SCLC. Italy (17%, n= 34), the UK (17%,
n=33), and Spain (16%, n=31) contributed the most responses. The
respondents workplaces were: university hospital (56%; n=111),
general public hospital (25%; n= 49), cancer centre (17%; n=34),
private centre (n=3) and other (n=1).
The majority of respondents (88%, n=174) were aware of the
CONVERT trial at the time of completing the survey and 21% (n= 42)
had included patients in the trial. Concurrent CTRT was considered the
standard of care in fit patients (n= 179, 90%) compared to sequential
treatment. OD was the most commonly used regimen, but the use of
concurrent BD radiotherapy increased after the publication of
CONVERT (n=59/186, 32% prior to and n=78/187, 42% after the
publication, p= 0.053; Table 1). Radiation oncologists preferred BD
radiotherapy more often than the other specialties (before CONVERT:
73% (n=43/59) versus 27% (n= 16/59), respectively, p= 0.004;
after CONVERT: 71% (n=55/78) versus 29% (n=23/78), respec-
tively, p= 0.004; no difference according to the type of institution).
60–66 Gy in 30–33 fractions was the most commonly prescribed OD
radiotherapy regimen (n= 76/120, 61%). The main reasons for not
implementing BD radiotherapy after the CONVERT publication (“tick
all that apply” answer) were logistical issues (n=88, 44%), incon-
venience for patients (n= 56, 28%), and the absence of a statistical
survival difference between the two arms in the CONVERT trial
(n= 38, 19%). Cisplatin-etoposide was considered the standard che-
motherapy regimen in the concurrent CTRT setting by 92% (n=182)
of respondents. 77% (141/182) reported delivering 4 cycles and 23%
(41/182) deliver 6 cycles of chemotherapy. G-CSF (granulocyte colony-
stimulating factor) was used by 39%, either routinely or as secondary
prophylaxis.
Regarding the staging investigations routinely carried out before
CTRT, 163 (83%) reported using positron emission tomography-com-
puted tomography (PET-CT) and 129 (65%) brain magnetic resonance
imaging (MRI). Furthermore, 55 (28%) used brain computed-tomo-
graphy and 14 (7%) did not image the brain at all.
With regards to follow-up and response evaluation, chest computed
tomography (CT) was the most commonly used imaging modality (95%
(n= 189) and 94% (n=186), respectively). Only 14% (n=29) fol-
lowed up patients with PET-CT. More than half (60%, n=118) of the
respondents did not routinely image the brain during follow-up. Of the
80 respondents who reported imaging the brain, MRI (45%, n=36/80)
was used less frequently than CT scans (55%, n=44/80). PCI was
routinely used in patients who had not progressed after CTRT (n= 187,
94%). The most commonly prescribed PCI dose was 25 Gy in 10 frac-
tions (n= 158, 80%) and more than half of respondents did not apply
an upper age limit (n=104, 53%). The median upper age limit was 75
years (47/94: 50%; range 65–81 years) for the other 94 respondents.
The main research questions of interest in LS-SCLC were 1) in-
tegrating novel targeted therapies-immunotherapies (n=160, 81%), 2)
PCI (+/- hippocampal-avoidance) vs. MRI surveillance (n= 140, 71%)
and, 3) biomarker driven trials to identify patients most likely to benefit
from CTRT (n=92, 46%).
4. Discussion
This European survey, designed to evaluate the impact of the
CONVERT trial publication on routine practice showed that the use of
BD radiotherapy increased after the CONVERT publication (32% prior
to and 42% after the publication). A public poll on Twitter organised
after CONVERT was published received 143 votes, almost half of which
(48%) chose BD over OD radiotherapy. This poll also suggested that the
results of the CONVERT trial are influencing oncologists' opinions [9].
Another analysis reported that BD radiotherapy increased after the
2000s (21% after vs. 8% before) [6]. However, despite evidence from
randomised trials, OD remains the most prescribed radiotherapy frac-
tionation. In this analysis, the main reasons for not implementing BD
were due to logistical issues (44%), inconvenience for patients (28%),
and the absence of a statistical survival difference between the two
arms of the CONVERT trial (19%, which is a misinterpretation given the
superiority trial design).
In an American survey conducted before the CONVERT trial pub-
lication, 60% (n=184) of clinicians preferred administering OD
radiotherapy, mainly (130/184: 71%) because it is more convenient for
patients [7]. It should however be emphasised that most departments
only treat small numbers of LS-SCLC patients each year. The gap be-
tween BD fractions is a minimum of 6 h and the treatment is delivered
over 3 weeks rather than over 6.5 weeks with OD radiotherapy, making
BD radiotherapy a feasible treatment option for patients. BD radio-
therapy toxicity has also substantially decreased with modern radiation
techniques and smaller volumes of oesophagus are being treated. In the
Turrisi study, one third of patients experienced grade 3+ radiation
esophagitis compared to< 20% in CONVERT [4,8]. Furthermore, in
CONVERT < 5% patients developed G3+ pneumonitis [8].
Our results also show a high level of interest in clinical research for
Table 1
Type of preferred radiotherapy delivered in the concurrent setting.
Before CONVERT
publication
Total=186*
N (%)
After CONVERT
publication
Total=187*
N (%)
OD
Preferred regimen
127 (68)
60-66 Gy: 76/127 (60)
109 (58)
60-66 Gy: 72/109 (66)
BD
Preferred regimen
59 (32)
45 Gy: 58/59 (98)
78 (42)
45 Gy: 78/78 (100)
* excluding respondents that never used concurrent CTRT.
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LS-SCLC. Ongoing trials in LS-SCLC are assessing immune checkpoint
inhibitors (81% of respondents were interested in integrating novel
targeted therapies-immunotherapies) concurrently with (pem-
brolizumab, NCT02402920) or after CTRT (durvalumab+ tremeli-
mumab, durvalumab, and placebo, NCT03703297; nivolumab and ipi-
limumab, NCT02046733: STIMULI recently closed prematurely). A
recent trial showed a beneficial effect on survival when the immune
checkpoint inhibitor atezolizumab was added to chemotherapy in ex-
tensive-stage SCLC, indicating that progress is being made in some as-
pects of the treatment of SCLC [10]. 71% of respondents also expressed
an interest in a trial comparing PCI (+/- hippocampal-avoidance) vs.
MRI surveillance (71%). In line with the latest European Society for
Medical Oncology (ESMO) guidelines [2,3], most respondents used PCI
routinely (94%) without upper age limits (53%). Brain MRI is generally
used for baseline staging (65%, 28% using brain CT and 7% not imaging
the brain at all) but not for follow-up (n=36/198, 18%). Of note, the
risk of developing brain metastases after PCI was the same in both arm
of the CONVERT trial [11]. As of early 2019, the cognitive impact of
hippocampal-avoidance (HA) PCI in the PREMER-TRIAL
(NCT02397733) has been reported in an abstract, where HA-PCI com-
pared to conventional PCI revealed a non-significant decline by ≥ 5
points at HVLT-R total recall score in 28% of the total group [12]. The
final results of further studies evaluating brain MRI surveillance and
mature results on HA-PCI in LS-SCLC (NCT02635009: NRG CC003;
NCT01780675: HA-PCI; NCT02058056: SAKK 15/12) are awaited.
As previously described [13], the inherent limitations of this type of
survey include the absence of a known response rate and a potential
selection bias. We do not have data on the total number of physicians
who received the survey as it was circulated by the national societies.
Most respondents were from Western European centres and the net-
works used to distribute the questionnaire generally targeted a specific
population (physician members of scientific societies and those working
in teaching hospitals). These groups may have been more likely to
participate and be more interested in clinical trials.
SCLC guidelines have not been updated since the publication of the
CONVERT trial [2,3]. ESMO and American Society for Radiation On-
cology (ASTRO) SCLC guidelines will be published in 2020. A repeat
survey of practice should ideally be undertaken after the guidelines
have been updated.
5. Conclusion
Once daily radiotherapy (60–66 Gy in 30–33 fractions) remains the
most prescribed radiotherapy fractionation, despite the findings sug-
gested by the CONVERT trial.
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